China Gender-affirming Hormone Therapy Study
Conditions:   Transgender;   Gender Incongruence Interventions:   Drug: GAHT for transgender men;   Drug: GAHT for transgender women Sponsors:   Peking University Third Hospital;   Tsinghua University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2022 Category: Research Source Type: clinical trials

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: RGT-419B;   Drug: RGT-419B in combination with hormonal therapy Sponsor:   Regor Pharmaceuticals Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
Condition:   High Risk Localized Prostate Cancer Intervention:   Sponsor:   Johnson & Johnson Pte Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: RGT-419B;   Drug: RGT-419B in combination with hormonal therapy Sponsor:   Regor Pharmaceuticals Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials